<DOC>
	<DOCNO>NCT00107107</DOCNO>
	<brief_summary>This multicenter , open-label extension study design examine long-term safety pramlintide treatment subject type 1 diabetes successfully complete treatment parent study 137-150 .</brief_summary>
	<brief_title>Study Long-Term Safety Pramlintide Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>The subject complete full dosing period Protocol 137150 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>pramlintide</keyword>
	<keyword>Symlin</keyword>
</DOC>